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Abstract
The HIV-1 viral infectivity factor (Vif) protein recruits an E3 ubiquitin ligase complex, comprising the cellular proteins elongin B
and C (EloBC), cullin 5 (Cul5) and RING-box 2 (Rbx2), to the anti-viral proteins APOBEC3G (A3G) and APOBEC3F (A3F) and induces
their polyubiquitination and proteasomal degradation. In this study, we used purified proteins and direct in vitro binding assays,
isothermal titration calorimetry and NMR spectroscopy to describe the molecular mechanism for assembly of the Vif-EloBC
ternary complex. We demonstrate that Vif binds to EloBC in twolocations, and that both interactions inducestructuralchanges in
the SOCS box of Vif as well as EloBC. In particular, in addition to the previously established binding of Vif’s BC box to EloC, we
report a novel interaction between the conserved Pro-Pro-Leu-Pro motif of Vif and the C-terminal domain of EloB. Using cell-
based assays, wefurther show that this interaction is necessary for the formation of a functional ligase complex, thus establishing
aroleof thismotif.We concludethatHIV-1 Vif engagesEloBC viaaninduced-foldingmechanismthatdoesnotrequire additional
co-factors,andspeculatethatthesefeaturesdistinguishViffromotherEloBCspecificityfactorssuchascellularSOCSproteins,and
may enhance the prospects of obtaining therapeutic inhibitors of Vif function.
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Introduction
The cullin-RING ubiquitin ligases form one of the largest family
of E3 ubiquitin ligases, and members are implicated in many
cellular functions such as the cell cycle, signal transduction,
transcription, circadian clock, development, DNA replication and
protein quality control [1]. All members of this family are
composed of a cullin E3 core and a specificity factor, which will
select the appropriate substrate for ubiquitylation [2]. One such
E3 core is composed of elongin B (EloB), elongin C (EloC), cullin 5
(Cul5) and RING-box protein 2 (Rbx2). A large number of
specificity factors can associate with this core [3] via a so-called
SOCS-box, composed of a BC-box responsible for binding to
EloBC, followed by a cullin-box responsible for selecting Cul5 [4].
The crystal structures of the specificity factors SOCS2 [5] and
SOCS4 [6] in complex with the EloB-EloC heterodimer (EloBC)
have shown that the BC-box forms an a-helix, which binds to
EloC via specific hydrophobic interactions. The consensus cullin-
box sequence is composed of a Leu-Pro-Leu-Pro (LPLP) motif
followed by a a-helix presenting a hydrophobic face, but the
mechanism by which it specifies Cul5 engagement remains to be
elucidated. Importantly, no system has yet been reported to study
the in vitro binding of specificity factors to EloBC. Indeed, it has
been shown that one such specificity factor, SOCS3, does not bind
to EloBC when purified separately, but requires co-expression to
form a SOCS3-EloBC ternary complex [7].
The HIV-1 encoded Vif protein is required for virus infectivity
and serves as a specificity factor to the EloBC-Cul5-Rbx2 E3 core.
Its substrates are the cellular intrinsic restriction factors APO-
BEC3G (A3G) and APOBEC3F (A3F), which are targeted by this
E3 ligase for poly-ubiquitination and degradation in the protea-
some [8,9,10] (Figure 1). Several motifs in the N-terminal portion
of Vif have been shown to be necessary for its interaction with
A3G and/or A3F [11,12,13,14,15] (summarized in Figure S1), but
this interaction remains poorly understood at the molecular level.
Vif binds to EloC via its BC-Box [9] (Figure 1 and S1), and
interacts with Cul5 via a unique zinc-finger motif upstream of the
BC-box [16,17,18,19,20]. HIV-1 Vif also contains a well-
conserved Pro-Pro-Leu-Pro sequence (PPLP) downstream of the
BC-Box (Figure 1 and S1), that is essential for Vif function [21],
but its precise role remains unclear. Specifically, contradictory
reports have linked this motif to the multimerization of Vif [22], or
to the interaction with Cul5 [20], A3G [23] or HIV-1 reverse
transcriptase [24]. This PPLP motif is followed by a stretch of 12
conserved residues (Figure S1), but these can be removed without
impairment to Vif function [21].
Studying the biochemical properties of the SOCS-box of Vif
could provide clues as to how this protein contributes to the
PLoS Pathogens | www.plospathogens.org 1 June 2010 | Volume 6 | Issue 6 | e1000925formation of a functional E3 ligase, as well as shed light on how
cellular factors can form similar E3 complexes. From this
perspective, we applied a range of structural, biochemical and
genetic methods to characterize the interaction between Vif and
EloBC. We were able to show that the BC-box of Vif is
unstructured in the unbound state, and forms an a-helix only upon
binding to EloC, as previously indicated [25]. We also demon-
strated a novel interaction between the PPLP motif of Vif and the
EloB subunit of EloBC. This interaction requires the binding of
the BC-box of Vif to EloC, and is coupled to the folding of an a-
helix at the C-terminus of EloB. Finally, we also confirmed that
the integrity of the PPLP motif is essential for the assembly of
biologically active complexes containing Vif and Cul5 [20].
Altogether, these data indicate that the Vif specificity factor binds
to the EloBC complex by an induced-folding mechanism. In
addition, they reveal a previously unknown interaction between
EloB and Vif, which may also be important for the binding of
other specificity factors.
Results
Biochemical characterization of the Vif-EloBC interaction
The lack of solubility of the HIV-1 Vif protein has impaired its
biochemical and structural characterization [26]. In order to
overcome this issue, we expressed and purified an extended region
of Vif containing the SOCS-box (residues 139–176) fused to a
solubility enhancement tag (SET) [27] at the N-terminus, and a
hexahistidine tag at the C-terminus (subsequently referred to as the
wild type Vif SOCS-box protein) (Figure S2A). In addition, we
engineered several mutated derivatives of this fusion, as summa-
rized in Figure 2A: two known biologically inactive mutations,
corresponding to triple alanine substitutions in the BC-box
(DSLQ) or the PPLP motif (DPPL), and a C-terminal truncation
to the boundary of the BC-box (referred to as the BC-box protein).
As expected, all these proteins eluted as monomers in gel filtration
(data not shown), and the monomeric state of the wild type protein
was further confirmed by analytical ultracentrifugation (Figure
S2B). From these results, we conclude that the PPLP motif is not
sufficient to induce multimerization of Vif, contrary to a previous
report [22].
We then used a gel filtration assay to monitor binding of the Vif
SOCS-box protein to EloBC purified from bacteria [7] (Figure
S2A). As shown in Figure 2B, the wild type protein co-eluted with
EloBC, at the elution volume expected for a 1:1:1 Vif:EloB:EloC
complex, and SDS-PAGE of the elution fractions, as well as
analytical ultracentrifugation of the complex (figure S2D),
confirmed this stoichiometry. As expected, the DSLQ protein
eluted later than EloBC (Figure 2B), indicating that this protein is
unable to bind to and form a stable complex with EloBC,
confirming the essential role of the BC-box motif in binding to
EloBC. The DPPL protein, as well as the BC-box protein, also co-
eluted with EloBC (Figure 2B), confirming that the BC-box of Vif
is sufficient for EloBC binding in this assay.
We subsequently used isothermal titration calorimetry (ITC) to
quantify the interaction between Vif and EloBC. Titration of the
wild type protein against EloBC could be fitted to a single binding
model, with a dissociation constant (Kd) of 1.2 mM (Figure 2C),
which is in the lower range of typical values for protein-protein
interactions [28]. As expected, the DSLQ protein did not show any
significant binding (Figure 2C). The BC-box protein had slightly
lower affinity (Kd=2.2 mM), but the DPPL protein displayed an
affinity similar to the wild type (1.25 mM). This suggests that the
modest but reproducible affinity decrease measured for the BC-
box protein may not be a specific effect of binding, but rather may
reflect size-related properties of the truncation, possibly related to
the diffusion rate in solution [29].
Importantly, the changes of enthalpy and entropy upon binding
were lower for the BC-box protein than for the wild type protein
(Figure 2D). Significantly, the DPPL protein also showed
Figure 1. HIV-1 Vif forms an E3 complex to promote the
degradation of A3G. Schematic representation of the E3 ubiquitin
ligase complex formed by HIV-1 Vif, with motifs reported to be required
for the interaction with Cul5 and EloBC indicated. Adapted from
reference [18].
doi:10.1371/journal.ppat.1000925.g001
Author Summary
HIV-1 is the etiologic agent of AIDS. Current therapies are
based on cocktails of anti-viral drugs that inhibit viral
enzymes essential for virus replication, but this strategy
has several shortcomings, including the development of
drug-resistant virus strains. Consequently, pharmacologic
strategies that interfere with additional aspects of HIV-1
replication have the potential to enhance HIV-1 treat-
ments. The HIV-1 Vif protein is a promising target for the
development of new anti-HIV-1 therapeutics; it functions
to counteract the cellular proteins A3G and A3F, two
components of a human anti-viral defence mechanism. Vif
accomplishes this by hijacking a cellular complex (com-
prising the proteins EloB, EloC, Cul5 and Rbx2), which then
eliminates A3G and A3F from infected cells by degrada-
tion, therefore evading their anti-viral effect. Here, we used
purified proteins to reconstitute in vitro the recruitment of
this complex by HIV-1 Vif. Using structural and biochemical
methods, we dissected the different events involved in
Vif’s interaction with the EloBC complex. Our results reveal
fundamental differences with cellular proteins known to
recruit this complex, suggesting that Vif possesses unique
features that could be targeted by pharmacologic
intervention, without disturbing normal cell functions.
The assays reported here could be utilized for the
discovery of such inhibitors.
Biophysical Studies of the Vif-EloBC Interaction
PLoS Pathogens | www.plospathogens.org 2 June 2010 | Volume 6 | Issue 6 | e1000925Figure 2. Biochemical analysis of the Vif-EloBC interaction. (A) Schematic representation of the Vif SOCS-box constructs and mutants used in
this study. The amino acid sequence is indicated on top, with the mutated residues in gray. (B) Gel filtration binding assay. The Vif SOCS-box and
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indicating that the PPLP motif contributes to EloBC binding but
does not affect the overall dissociation constant for this interaction.
The BC-box of Vif is unstructured in the absence of EloBC
A recently published crystal structure of the Vif BC-box in
complex with EloBC [25] confirmed that the BC-box assumes an
a-helical conformation when bound to EloBC, and contacts EloC
via hydrophobic interactions. We therefore used NMR spectros-
copy to determine the conformation of the SOCS-box of Vif when
unbound, and to investigate binding to EloBC at the amino acid
level. The
15N-HSQC spectrum of the wild type Vif SOCS-box
protein is shown in Figure 3A (red spectrum); this spectrum is
consistent with a well-folded protein, having a good dispersion of
peaks between 6 ppm and 11 ppm in the
1H dimension. However,
comparison of these data to a spectrum of the SET tag alone [30]
revealed that most peaks are formed by residues belonging to the
tag and not to Vif. A range of triple-resonance and residue-specific
labelling experiments allowed us to assign the resonances
corresponding to the backbone atoms of approximately 85% of
the Vif portion of the fusion protein (Figure 3A), which was
confirmed by comparing
15N-HSQC spectra of the mutant
proteins described above (data not shown). Interestingly, all the
peaks assigned to the Vif SOCS-box are located between 7.9 and
8.4 ppm in the
1H dimension. Spectra of this nature are
characteristic of a random coil conformation, where residues are
mutated variants were mixed with equimolar amounts of EloBC and run through a gel filtration column, with the UV280 trace shown on top. The
eluted fractions were collected and run on a 16% polyacrylamide gel and stained with Coomassie blue (bottom). (C) ITC binding assay. The Vif fusion
proteins were titrated against EloBC. The raw data are shown on top, the heat integration at the bottom. The resulting Kd is given for each construct,
except for the DSLQ protein, for which no binding was observed. (D) Thermodynamic analysis of the ITC binding assay. The binding free energy (DG),
enthalpy (DH) and entropy (DS) are plotted for the Vif fusions proteins binding to EloBC. The DSLQ protein is not shown as no binding was observed.
doi:10.1371/journal.ppat.1000925.g002
Figure 3. NMR spectroscopy of the Vif SOCS-box. (A)
15N-HSQC spectrum of Vif SOCS-box protein in the free state (red spectrum) and bound to
EloBC (blue spectrum), with the sequence of the Vif SOCS-box shown on top. The peaks assigned to residues belonging to the Vif SOCS-box are
indicated; some peaks are omitted for clarity. (B) Secondary structure of the Vif SOCS-box wild type protein, measured with the software SSP using
chemical shifts values. The portion of this protein corresponding to the Vif SOCS-box is indicated in red, with the location of the BC-box indicated.
The numbering indicated below corresponds to the SET tag (black) and the Vif sequence (red).
doi:10.1371/journal.ppat.1000925.g003
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of the Vif SOCS-box was then confirmed by measuring the
chemical shift deviation, using the software SSP [32], as shown in
Figure 3B.
Structural changes in Vif’s SOCS-box when bound to
EloBC
We next recorded a
15N-HSQC spectrum for a complex of the
15N-labelled wild type Vif SOCS-box protein with unlabelled
EloBC (spectrum shown in blue in Figure 3A). While most of the
peaks corresponding to the SET tag are identical to the unbound
spectrum, the peaks corresponding to the BC-box are now absent
(Table S1). As the BC-box of Vif is known to be helical when
complexed with EloBC [25], we anticipated that new peaks
corresponding to the helical conformation of BC-box residues
might appear. The absence of peaks, even in excess of EloBC,
indicates that the Vif-EloBC complex is dynamic, with conforma-
tional fluctuation in the millisecond-to-microsecond range. As a
consequence, the residues involved in the interaction could not be
observed in
15N-HSQC spectra. We note, however, that the
dynamic property of this interaction may be caused by the SET-
tag and may not hold true for the full-length, untagged Vif protein.
It is interesting to note that the peak assigned to Leu-163, the
leucine of the PPLP motif, also appears to be missing in the bound
spectrum (Figure 3A). As this peak is located in a highly
overlapped region of the spectrum, we used residue-specific
labelling to study this residue. In particular, the Vif SOCS-box
protein was uniformly
15N-labelled in the presence of 1-
13C
proline. This results in the carboxyl group of proline residues being
13C-labelled, meaning that only residues immediately C-terminal
to prolines are observed in HNCO spectra [33] (Figure 4A). NMR
spectra confirmed unambiguously that the intensity of the peak
corresponding to Leu-163 (and to a lesser extent Ser-165) strongly
decreased upon EloBC binding (Figure 4B), indicative of their
participation in the interaction. In contrast, the peak correspond-
ing to Lys-157, located between the BC-box and the PPLP motif,
was not affected upon binding. This confirms the involvement of
the PPLP motif of Vif in binding to EloBC, as suggested by the
ITC experiments described above.
EloC becomes structured upon binding to the BC-box of
Vif
We then investigated the structural changes that occur in EloBC
upon binding to Vif. The
15N-HSQC spectrum of unbound
EloBC indicates that the complex is only partly folded, with some
unresolved resonances at the centre of the spectrum (Figure 5A).
Analytical ultracentrifugation of EloBC demonstrated that this
complex forms a heterodimer in solution (Figure S2C), confirming
that the unresolved resonances are not caused by aggregation. It
should be mentioned, however, that these data were best fitted to a
model in which some residual, non-interacting aggregate impuri-
ties are present (Figure S2C). Recent NMR studies of the EloBC
complex showed a similar
15N-HSQC spectrum for unbound
EloBC, and revealed that most of the well-resolved peaks
correspond to the ubiquitin-like domain of EloB, while the
majority of the peaks for EloC were missing [7].
The spectrum of EloBC bound to the wild type Vif SOCS-box
protein is characteristic of a well-folded protein complex
(Figure 5B), and is similar to the spectrum of EloBC bound to
the BC-box of SOCS3 [7]. This therefore indicates that EloC
acquires much of its structure upon ligand binding. The spectrum
of EloBC bound to the DPPL mutant is similar to the spectrum
bound to wild type (Figure S3), demonstrating that the structural
reorganization of EloC upon binding is driven by the interaction
between EloC and the BC-box of Vif.
The PPLP motif of Vif interacts with the C-terminus of
EloB
One prominent aspect of the
15N-HSQC spectrum of unbound
EloBC, which has not been reported previously, is the presence of
some very intense and poorly dispersed peaks, indicative of
residues that are in random-coil conformation and are highly
dynamic in the pico- to -nanosecond timescale. Triple-resonance
experiments allowed us to assign these peaks to the C-terminal tail
of EloB, specifically residues 101 to 118 (Figure S4A). Differences
in the buffer and/or temperature used for these experiments likely
explain why these peaks were not observed by others [7]. It is
worth noting that in the crystal structure of EloBC in complex with
SOCS2 [5], as illustrated in Figure S4B, there is no electron
density for residues 106 to 118 of EloB, consistent with the
presence of significant disorder in this region, but residues 101 to
104 form a well-structured a-helix. The spectrum reported here
suggests that these four residues are unstructured; we therefore
propose that this a-helix is not formed in unliganded EloBC.
In the
15N-HSQC spectrum of EloBC bound to Vif, the intensity
of the peaks assigned to the C-terminus of EloB was significantly
decreased, particularly for residues 101 to 104 (Figure 5A, 5C and
5D). An NMR titration of unlabelled wild type Vif SOCS-box
Figure 4. Proline labelling of the Vif SOCS-box protein. (A) NH
plane of the HNCO spectrum collected on
15N, 1-
13C proline-labelled Vif
SOCS-box protein (blue spectrum), overlapped with the
15N-HSQC
spectrum of this protein (red spectrum). (B) Titration of EloBC against
proline-labelled Vif SOCS-box, with the ratio of EloBC to Vif shown on
top. The peak for Leu 163 disappears upon binding, but the peak for Lys
157 is not affected. The peak for Ser 165 also decreases in intensity, and
is shifted upfield on both proton and nitrogen dimensions.
doi:10.1371/journal.ppat.1000925.g004
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15N-labelled EloBC (Figure 5A) confirmed that this
decrease in intensity occurs upon binding. For residues Asp-101, Val-
102, Met-103 and Lys-104, the changes in peak intensity upon
titration of the Vif SOCS-box protein could be fitted to Kd values of
1.71 mM, 0.43 mM, 1.73 mM and 3.56 mM respectively (Figure 5B),
which are close to the Kd value obtained by ITC of 1.20 mM. Taken
altogether, these data demonstrate that the decrease in intensity of the
peaks corresponding to residues 101 to 104 of EloB is caused by
binding to Vif.
A decrease in peak intensity in
15N-HSQC spectra could be
explained by: (1) line broadening upon binding, owing to the
increase in complex size and/or changes in dynamic properties of
the residue forming this peak, or (2) by the appearance of a new
peak representing changed conformation in the bound state. In
order to discriminate between these two possibilities we measured
relaxation times for peaks assigned to residues 101 to 118 of EloB,
and the resulting T1/T2 ratios are shown in Figure S5: the peak
intensities and fitting parameters are given in Table S2. This ratio
Figure 5. NMR spectroscopy of EloBC.
15N-HSQC spectrum of protonated EloBC (A) or uniformly-deuterated EloBC bound to unlabelled wild type
Vif SOCS-box protein (B). The best spectra available were used for illustration, but similar spectra were recorded on several occasions using different
protein preparations. The spectrum of free EloBC shows some well dispersed peaks, but also significant overlap exists between 7.5 and 8.5 ppm in
the
1H dimension, indicative of an unstructured domain. The spectrum of bound EloBC is much better resolved, with more peaks corresponding to
well-folded domains.
doi:10.1371/journal.ppat.1000925.g005
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properties of individual amino acids [34]. It is evident that this T1/
T2 ratio is higher in the EloBC-Vif complex for residues 106 to
111, indicating that the decrease in peak intensity upon binding
observed for these residues is due to line broadening, presumably
caused by the increase in molecular weight. In contrast, for
residues 101 to 103 the T1/T2 ratios are identical for the free and
bound states of EloBC (Figure S5), indicating that there is no
significant broadening of the peaks upon binding for residues 101
to 103, and therefore that altered conformation underlies the
decreases in their intensity. From this observation, it can be
concluded that the peaks observed for these three residues in the
spectrum of EloBC bound to the Vif SOCS-box protein
correspond to a fraction of EloB where these residues do not
adopt their bound conformation. Since the Vif SOCS-box-EloBC
complex was purified in excess of Vif, this observation is unlikely to
be caused by the presence of free EloBC, and most likely reveals
the transient nature of the PPLP-mediated interaction. Specifical-
ly, we propose that residues 101–104 of EloB form an a-helix upon
binding to Vif, reminiscent of that found in the crystal structures of
EloBC bound to SOCS proteins [5,6]. In the spectrum of EloBC
bound to the DPPL protein, the intensity of these four peaks is also
reduced, but to a significantly lesser extent, particularly for
residues 101 to 104 (Figure 6C right panel, and Figure 6D), and
we attribute this to peak broadening rather than new peak
formation. These data suggest that residues 101 to 104 of EloB
interact, most likely directly, with the SOCS-box of Vif, and that
binding is dependent on the integrity of the PPLP motif.
As demonstrated previously, EloBC does not show any
significant binding to the SOCS-box of Vif when the SLQ motif
is mutated to AAA. We therefore postulated that the interaction
between EloB and the PPLP motif of Vif is dependent upon the
binding of EloBC to the BC-box of Vif (as illustrated on Figure 7).
To test this, we hypothesized that EloBC bound to the BC-box of
Vif should be able to bind to the PPLP motif when provided
separately. Using ITC, we were able to measure the binding of a
complex between EloBC and the BC-box protein to a BC-box
deficient Vif fusion protein (i.e., the DSLQ protein with an intact
PPLP motif) (Figure 7B); neither EloBC alone (Figure 7A) nor the
BC-box protein alone (Figure S6A) gave any measurable binding
to the BC-box deficient protein. Accordingly, this experiment
demonstrated that the PPLP motif of Vif forms a second
interaction with EloBC, but only when EloBC had already
engaged the BC-box, The specificity of this interaction was further
demonstrated by performing this experiment using a double-
mutant Vif SOCS-box protein in which the SLQ and PPLP motifs
were both disrupted (Figure S6B). As anticipated, no interaction
with the preformed EloBC-Vif BC-box complex occurred,
confirming the requirement for an intact PPLP motif.
To confirm that this interaction is driven by residues 101 to 104
of EloB, we engineered a deletion of the C-terminal 17 residues of
EloB (EloB1–101); this deletion did not compromise either the
formation or the solubility of the EloBC complex (hereafter
referred to as EloBCD) (Figure S6C). Similar to full length EloBC,
EloBCD bound to the wild type Vif SOCS-box protein but not to
the DSLQ protein (data not shown, Figure S6D). However, the
complex of EloBCD bound to the BC-box protein failed to show
additional binding to the DSLQ protein, as measured by ITC
(Figure 7C). We note that some energy release was observed for
the first few measurements, possibly caused by destabilization of
the EloBCD-BC-box complex (Figure 7C). In summary, these data
confirm that the interaction between the PPLP motif of Vif and
EloBC is dependent on residues 101 to 104 of EloB (summarized
in Figure 7, right panels).
The interaction between the PPLP motif and EloB is
necessary for the formation of a functional E3 ubiquitin
ligase complex
We next investigated the relevance of this newly described
PPLP-EloB interaction to Vif function in living cells. We tested the
functionality of several mutant Vif proteins in single-cycle HIV-1
infectivity assays, where infection requires the degradation of A3G
in virus producing cells. As shown in Figure 8A, the DPPL mutant
of Vif was inactive, as were the previously described DSLQ and
C114S mutants. A second mutation of this motif, where PPLP was
mutated to APLA, also abrogated Vif function, whereas deletion of
the residues downstream of the putative cullin-box (D16) was
inconsequential. As expected, immunoblot analysis of the
corresponding cell lysates confirmed that the wild type and D16
Vif proteins induced the degradation of A3G, but that all the
proteins containing inactivating mutations failed to do so
(Figure 7B).
Having demonstrated above that the PPLP motif of Vif forms a
secondary site of interaction between Vif and EloB, we postulated
that this interaction is required for the recruitment of Cul5. To test
this hypothesis, we measured the binding of Vif to HA-tagged
Cul5 by co-immunoprecipitation from lysates of transfected cells
(in the absence of A3G). As shown in Figure 7C, Cul5 interacts
with wild type Vif and the D16 truncated protein. Neither the
DSLQ nor C114S proteins were detected in the recovered
fraction, confirming that the recruitment of EloBC via the BC-
box, as well as the integrity of the HCCH domain, are both strictly
required for binding to Cul5. Neither the DPPL nor the APLA
protein efficiently co-immunoprecipitated with Cul5, confirming
that the PPLP motif is important for the recruitment of Cul5. A
faint band could be observed in the recovered fraction for the
DPPL protein; since we have demonstrated above that this
mutation abrogates the interaction between HIV-1 Vif and the C-
terminal helix of EloB, it appears that in the context of over-
expressed protein minimal binding to Cul5 is still possible for this
protein. This would provide an explanation for the discrepancies
between the study by Yu et al. [20] and the results reported by
Donahue et al. [23]: the former reported a loss of binding to Cul5
in immunoprecipitation experiments for mutations of the PPLP
motif, while the later did not. Given that this weak interaction was
not detected with the APLA protein, we suggest that this mutation
may also abrogate an interaction between Vif and Cul5. This
would be consistent with the model articulated by Stanley et al. [25],
where the C-terminal proline of the PPLP motif is proposed to
contact loop 2 of Cul5.
Discussion
Here, we have reported a dissection of the interactions between
the HIV-1 Vif protein and the EloBC heterodimer. Our data
indicate that at least two binding steps occur, that both induce
structural changes in the constituent proteins, and that these
changes are necessary for other essential steps in the assembly of a
competent E3 ubiquitin ligase complex. This induced-folding
mechanism, shown in Figure 9, can be summarized as incorpo-
rating the following steps (recognizing that some of these may take
place concurrently or consecutively): (1) in the free state, the
SOCS-box of HIV-1 Vif is unstructured; (2) when Vif encounters
EloBC, its BC-box forms an a-helix and binds to EloC, which also
becomes structured (step 1); (3) once Vif is bound to EloC, its
PPLP motif interacts with residues 101–104 of EloB, which forms
an a-helix (step 2); and (4) this second interaction between Vif and
EloBC, together with the interaction between Cul5 and Vif’s
Biophysical Studies of the Vif-EloBC Interaction
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assembly of a functional ubiquitin ligase.
These studies were made possible by our capacity to isolate
soluble Vif peptides and EloBC independently, and then to
reconstitute binding interactions in vitro. In this regard, these
studies are fundamentally distinct from previous analyses of
interactions between EloBC and SOCS proteins [7] or the VHL
protein [35] where complex formation necessitated co-expression
of the components, thus precluding experiments of the genre
discussed here. It is not known if this requirement of co-expression
for complex formation observed in vitro correlates to a functional
property of these proteins in vivo. However, it is worth noting that
the VHL protein, a specificity factor for an E3 core comprising
EloBC, cullin 2 and Rbx1, has been reported to require the
chaperone TRiC in order to bind to EloBC in vivo [36], providing
a potential explanation for the lack of binding reported for
proteins purified separately. It is tempting to speculate that the
capacity of HIV-1 Vif to bind to EloBC in vitro reflects a functional
Figure 6. The PPLP motif of Vif interacts with residues 101–104 of EloB. (A) Unlabelled Vif SOCS box protein was titrated against
15N-
labelled EloBC, and
15N-HSQC spectra were recorded for each point of the titration. For these spectra, the contrast is set in order to visualize only the
very intense peaks assigned to the C-terminus of EloB. (B) The relative intensities of the peaks assigned to residues 101–104 of EloB were fitted to
corresponding Kd values using a script written with the Mathematica software. The Kd values thus obtained are comparable to the values obtained by
ITC. (C)
15N-HSQC NMR spectrum of EloBC alone (left panel), bound to the wild type Vif SOCS-box protein (middle panel) or to the DPPL protein (right
panel); these spectra are shown with a low contrast in order to visualize only the very intense peaks. (D) For each peak assigned to the C-terminus of
EloB, the S/N was measured using SPARKY and plotted as a relative intensity compared to the S/N of peaks in the unbound protein.
doi:10.1371/journal.ppat.1000925.g006
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chaperone involvement: this may be indicative of a mechanism by
which Vif is able to out-compete other specificity factors to form
an E3 ligase complex.
Both NMR and ITC demonstrated that the PPLP motif of Vif
interacts specifically with residues 101–104 of EloB. The canonical
SOCS-box motif possesses a similar LPLP motif [3], and one
question that arises is whether this motif also interacts with EloB In
the crystal structure of the SOCS2-EloBC complex [5], the LPLP
motif is located in a hydrophobic pocket formed by EloC and residues
101–104 of EloB (Figure S7), particularly the valine and methionine
at positions 102 and 103. Interestingly, it has been shown that the C-
terminal tail of EloB up to residue 104 is strictly conserved in all
species, including Drosophilaand Caenorhabditis[37], though its rolehas
remained unexplained to date. We therefore propose that the LPLP
motif of SOCS-box proteins ultimately binds to EloB in an analogous
way to the PPLP motif of HIV-1 Vif, and that these two motifs may
play a similar role in recruiting Cul5.
We note that both the in vitro binding and the co-immunopre-
cipitation experiments presented here were performed in the
absence of A3G, demonstrating that Vif is capable of recruiting
the EloBC-Cul5-Rbx2 complex independently of its interaction
with A3G. It is possible, however, that prior binding to A3G may
alter the kinetics of the interactions discussed here, but such
experiments await the purification of the amino-terminal region of
A3G that binds Vif. Similarly, it also remains to be determined
whether binding of HIV-1 Vif to A3G can occur in the absence of
the E3 ubiquitin ligase complex. Interestingly, it has been reported
that the PPLP motif also plays a role in binding to A3G [23,37],
which may suggest that the interaction between Vif and EloBC
and/or Cul5 affects binding to A3G.
Altogether, the data presented here suggest a refined model for
the formation of the Vif-EloBC-Cul5 E3 ubiquitin ligase complex.
We demonstrate that the binding of Vif to EloBC is measurable in
vitro, unlike other SOCS-box proteins, a feature that could be
exploited to develop small molecules that specifically inhibit Vif-
EloBC complex formation. In addition, we describe a new
interaction between the cullin-box of HIV-1 Vif and the C-
terminal tail of EloB, and propose that a similar interaction may
occur in all SOCS-box proteins. As such, these observations
extend the current understanding of how cullin-RING ubiquitin
ligases engage their specificity factors and substrates.
Materials and Methods
Plasmids and cloning
Vif SOCS-box fusion proteins were expressed in E.coli using
pET30-GBFusion1 [27], a vector containing the GB1 gene at the
N-terminus followed by a C-terminal His6 tag, separated by a
BamHI restriction site. This site was used to insert fragments
spanning the HIV-1 (HXB-3 isolate) Vif SOCS-box, or mutated
derivatives [21].
Figure 7. ITC measurement of the Vif-EloB interaction. For all panels, ITC data is shown on the left, with the raw data on top and the heat
integration at the bottom. A schematic representation of the experiment is shown on the right. (A) Titration of EloBC complex against the DSLQ
protein; no binding is observed. (B) Titration of the EloBC/Vif BC-box complex against the DSLQ protein. (C) Titration of the EloBCD/Vif BC-box
complex against the DSLQ protein; no binding is measured, but an endothermic reaction is observed instead.
doi:10.1371/journal.ppat.1000925.g007
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vector (Novagen). The sequences coding for full length (residues 1–
118) or truncated (1–101) EloB were expressed with an the N-
terminal His6 tag by insertion between the BamHI and HindIII of
MCS1. EloC (residues 16–111) was cloned into the MCS2 using
the NdeI and XhoI sites.
For the infectivity assay, the vif-deficient HIV-1 provirus, pIIIB/
Dvif; the HIV-1 Vif expression vector, pcVIF, its corresponding
control, pcDVIF, as well as the A3G expression vector, pA3G,
have been described [38]. Previously defined mutated vif genes
were introduced into pcVIF [21]. The Cul5-HA expression vector,
pCUL5HA, was created by inserting the Cul5 cDNA into the
pCMV4HA plasmid.
Protein expression and purification
The Vif SOCS-box fusion proteins were expressed in E.coli
strain BL21(DE3), and EloB/EloBD and EloC were co-expressed
in E.coli strain BL21(DE3). Cells were grown in LB with 50 mg/l
kanamycin (Vif proteins) or 100 mg/l ampicillin (EloBC) at 37uC
until OD600<0.5, and expression was induced by adding 1 mM
IPTG for 4 hours. Cells were harvested, resuspended in SOCS
buffer (20 mM Tris pH 8.0, 500 mM NaCl, 0.05% sodium azide,
protease inhibitor coctail [Roche]) or BC buffer (20 mM Tris
pH 8.0, 10 mM imidazole, 0.05% sodium azide, protease
inhibitor cocktail [Roche]) for the Vif SOCS-box and EloBC
respectively. The suspension was then sonicated, clarified by
centrifugation at 45,000 g for 50 min. and the supernatant applied
Figure 8. The interaction between the PPLP motif of Vif and EloB is necessary for binding to Cul5. (A) The activity of Vif proteins was
measured by the capacity to overcome the anti-viral action of A3G in a single-cycle infectivity assay. The data are represented as relative b-
galactosidase units normalised to HIV-1 with no A3G or Vif. The means of three experiments was used, with error bars representing the standard
deviation. (B) Immunoblot of the whole cell lysates from the producer cells used for infectivity assays. HSP90 is shown as a loading control. (C) Co-
immunioprecipitation of Vif with Cul5. 293T cells were transfected with plasmids expressing HA-tagged Cul5 and wild type or mutated Vif proteins,
and Cul5-HA was isolated using an a-HA antibody. Cell lysates and immunoprecipitates were analysed by immunoblotting for presence of Vif and
Cul5-HA.
doi:10.1371/journal.ppat.1000925.g008
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BC buffer. The resin was rinsed with SOCS/BC buffer, and then
with SOCS/BC buffer supplemented with 50 (or 25) mM
imidazole. The protein was eluted using SOCS/BC buffer plus
500 mM imidazole and fractions were analysed by SDS-PAGE,
pooled and concentrated using a 3 MWCO centricon (Milipore)
up to <5mg/ml. The samples were further purified by size-
exclusion chromatography, using a Superdex 75 column (GE
Healthcare) equilibrated in SOCS/BC buffer.
To form EloBC-Vif SOCS-box complexes, the concentrations
of the various purified components were estimated by measuring
their OD280. They were mixed at a 1:1:1 EloB:EloC:Vif SOCS-
box ratio and run on Superdex 75 gel filtration columns (GE
Healthcare) in complex buffer (50 mM Tris pH 7.5, 150 mM
NaCl, 0.05% sodium azide, protease inhibitor tablets [Roche]).
For NMR experiments the proteins were expressed in E.coli
strain BL21/DE3 in M9 minimal media supplemented with
15NH4Cl,
13C-labelled glucose,
2H2O, and/or 1-
13C proline
depending on the experiment. The proteins were purified as
above.
Isothermal titration calorimetry
All samples were dialysed into 50 mM Tris pH 7.5, 50 mM
NaCl, 0.05% sodium azide supplemented with protease inhibitors
[Roche]. ITC was performed using a VP-ITC calorimeter, except
for the titration of EloBC-Vif BC-box with the double-mutant
SOCS-box, which was performed using a ITC200 calorimeter
(both machines are manufactured by MicroCal, Inc., North-
ampton, MA). For the binding of the Vif SOCS-box protein to
EloBC, titrations were performed by injecting 90 aliquots of
6.167 ml of protein at <0.2 mM into the chamber containing
EloBC at 0.025 mM. For analysing PPLP motif binding, the
titrations were performed by injecting 30 aliquots of 9.12 ml of the
EloBC-Vif BC-box complex at 0.3 mM into the chamber
containing the DSLQ Vif SOCS-box protein at 0.02 mM.
Analytical ultracentrifugation
Sedimentation equilibrium experiments were performed using a
Beckman Optima XL-A analytical ultracentrifuge as described
previously [39]. Samples were prepared in 50 mM Tris pH 7.5,
50 mM NaCl, 0.05% sodium azide supplemented with protease
inhibitors [Roche], and data were acquired as an average of 25
absorbance measurements at a wavelength of 280 nm and a radial
spacing of 0.001 cm. Sedimentation equilibrium experiments were
performed at 4uC, at concentrations corresponding to A280 of 0.4,
0.6 and 0.8, and rotor speeds of 14,000, 17,000 and 20,000 RPM
for the Vif SOCS-box and EloBC alone, and 12,000, 14,000 and
16,000 RPM for the Vif SOCS-box-EloBC complex. The buoyant
molecular mass M(1-vr) for a EloBC heterodimer was calculated
to be 6965, using a solvent density of 1.00720, v of 0.7233 and a
molecular mass of 25656, based on the amino acid composition
using SEDNTERP (http://www.rasmb.bbri.org/). Similarly, the
buoyant molecular mass M(1-vr) for a monomer of the Vif SOCS-
box was calculated to be 3159, using a solvent density of 1.00720,
v of 0.7263 and a monomer molecular mass of 11767. Data for all
three concentrations was analysed simultaneously using a range of
models in Sigmaplot, as described previously [39]. Residuals were
calculated by subtracting the best fit of the model from the
experimental data.
NMR spectroscopy
For all NMR experiments, protein samples were dialysed in
NMR buffer (50 mM phosphate buffer pH 7.0 10% D2O, 0.05
sodium azide, protease inhibitor tablets [Roche]), and concentrat-
ed to 0.1–0.5 mM. Approximately 250 ml of samples were
transferred to Shigemi tubes for data acquisition.
For the wild type Vif SOCS-box protein, triple-resonance
experiments were collected on
15N,
13C-labelled protein, using a
Bruker Avance 700 MHz spectrometer equipped with a cryo-
probe. Residue-specific labelling experiments, as well as the
spectrum of the Vif SOCS-box in complex with EloBC, were
Figure 9. Schematic representation of the induced-folding
mechanism for the formation of Vif-EloBC-Cul5 complex.
Structure-based representation of the Vif-EloBC-Cul5 complex forma-
tion; for simplicity, the various binding events are shown in succession,
although in the absence of kinetic data the precise order of events
remains to be verified. Vif is represented by a red oval apart from the
SOCS-box, which was modelled on the crystal structure of the EloBC-Vif
BC-box complex [25] (PDB ID:3DCG). The structure of EloBC bound to
the BC-box was modelled on the NMR structure of EloBC bound to the
SOCS3 BC-box [7] (PDB ID: 2JZ3). The structure of EloBC bound to the
Vif BC-box and the PPLP motif was modelled on the crystal structure of
the EloBC-SOCS2 complex [5] (PDB ID:2C9W). The structure of Cul5 was
modelled on the crystal structure of Cul1 [46] (PDB ID:1LDJ). The green
dashed lines indicate interactions between HIV-1 Vif and Cul5.
doi:10.1371/journal.ppat.1000925.g009
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15N-labelled protein, using a Bruker AvanceIII
600 MHz spectrometer equipped with a cryoprobe.
For EloBC, triple-resonance experiments were collected on
15N,
13C-labelled protein, using a Bruker Avance 700 MHz spectrom-
eter equipped with a cryoprobe. Spectra of EloBC in complex with
the Vif SOCS-box, as well as relaxation data, were acquired on a
Varian Inova 800 MHz and a Bruker AvanceII 800 MHz, both
equipped with cryoprobes. The
15N-HSQC spectra of EloBC
bound to the Vif SOCS-box and mutant were acquired on
uniformly-deuterated EloBC, using a TROSY-based pulse
sequence; relaxation data were acquired on
15N-labelled protein.
All spectra were processed with NMRPipe [40] and analyzed
with SPARKY [41]. Sequential assignment was carried out using
an assignment software promgram ASSIGNER (Laponogov I.,
unpublished). Relaxation data were fitted using NMRView [42].
NMR titration data were fitted using a script written in the
Mathematica software suite.
Infectivity assay and coimmunoprecipitation
The HIV-1 infectivity assay has been described previously [38].
Briefly, 293T cells were transfected with 1 mg pIIIB/Dvif
(provirus), 0.5 mg pA3G and various amounts of pcVIF, or mutant
derivatives, to obtain a similar level of expression (the total amount
or DNA was balanced to 3 mg with pcDVif), using polyethyleni-
mine. After 24 h, the supernatant containing HIV-1 was harvested
and 50 ml was used to infect 10
5 TZM-bl indicator cells [43]. The
induced expression of b-galactosidase was measured after 24 h
using the Galacto-Star system (Applied Biosystems). The producer
cells were lysed in SDS-PAGE loading dye for analysis of protein
expression by immunoblotting using primary antibodies specific
for Vif [44], A3G [45] or HSP90 (Invitrogen). Bound antibodies
were detected using the Li-COR technology, with IRDye-labelled
secondary antibodies and an Odyssey imager.
For co-immunoprecipitation, 293T cells were transfected with
various amount of pcVIF or mutant derivatives, to obtain similar
levels of expression (balanced to 3 mg with pcDVif), and 2 mg
pCUL5HA. Cells were lysed in 250 ml IP buffer (50 mM Tris
pH 7.0, 150 mM NaCl, 0.5% Triton, protease inhibitor tablets
(Roche)), and incubated with Protein G agarose beads (Invitrogen)
and rabbit anti-HA antibody (Rockland) at 4uC for 3 h. The beads
were washed 4 times with IP buffer and resuspended in 25 ml gel
loading buffer. 10 ml of the immunoprecipitated samples, as well as
10 ml of cell lysate, were run on 16% acrylamide SDS-PAGE gel
and analysed by immunoblotting using primary antibodies specific
for Vif or HA (Covance), and Li-COR technology.
Supporting Information
Figure S1 HIV-1 Vif sequences alignment. The Vif sequence
from representative strains of several HIV-1 clades, along with a
Vif sequence derived from an SIV isolated from a chimpanzee,
were aligned using ClustalW [47] and the secondary structure was
predicted with Phyre [48] (The isolates used are 93BR020,
96CM_MP535, 90CF056, SE9280, ELI, NY5, 92BR025, MAL,
92NG083, CPZ_GAB1, YBF30 and ANT70 for the HIV-1 group
M subtypes F1, K, H, J, D, B, C, A, G, the chimpanzee SIV and
HIV-1 group N and O Vif sequences, respectively). The figure was
generated using ESPript [49]. The N-terminal half (residues 1–99)
is predicted to consist primarily of b-sheets, and contains motifs
implicated in binding to A3G/A3F. The C-terminal half (residues
100–198) is predicted to be mostly helical and contains the motifs
involved in forming the E3 EloBC-Cul5-Rbx2 ubiquitin ligase
complex.
Found at: doi:10.1371/journal.ppat.1000925.s001 (1.02 MB TIF)
Figure S2 Characterization of the Vif SOCS-box protein. (A)
SDS-PAGE gel of the purified proteins. For each purified protein
used in the binding assay, approximately 10 mg was run on a 16%
acrylamide SDS-PAGE gel and stained with Coomassie blue. All
proteins appear to be between 95 and 99% pure. (B) Analytical
ultracentrifugation of the Vif SOCS-box. The data shown here
were collected on a sample with OD280=0.8, at 20,000, and fitted
to a single ideal species with the molecular weight floated. (C)
Analytical centrifugation of EloBC. The data shown was collected
at loading concentrations corresponding to A280 values of 0.8
(circles), 0.6 (squares), and 0.4 (triangles), at 14,000 RPM. A shows
the data curves simultaneously fitted to a monomer + aggregate
non-interaction model, and gives and excellent fit, with the
residuals randomly distributed around zero. The residuals for a
single species and a monomer-dimer equilibrium respectively are
shown on the right, and it is clear that both of these fits are less
good. (D) Analytical centrifugation of EloBC-Vif SOCS-box
complex. The data shown was collected at loading concentrations
corresponding to A280 values of 0.8 (circles), 0.6 (squares), and 0.4
(triangles), at 12,000 RPM. A shows the data curves simulta-
neously fitted to a monomer + aggregate non-interaction model,
and gives and excellent fit, with the residuals randomly distributed
around zero. Residuals for a single species and a monomer-dimer
equilibrium respectively are shown on the right, and it is clear that
both of these fits are less good.
Found at: doi:10.1371/journal.ppat.1000925.s002 (2.73 MB TIF)
Figure S3 NMR spectrum of EloBC bound to the DPPL
mutant.
15N-HSQC spectrum of uniformly
15N,
2H-labelled
EloBC bound to unlabelled DPPL Vif SOCS box protein. This
spectrum is similar to the
15N-HSQC spectrum of EloBC bound to
wild type Vif SOCS box protein (Figure 5B).
Found at: doi:10.1371/journal.ppat.1000925.s003 (0.38 MB TIF)
Figure S4 The C-terminus of EloB. (A) The
15N-HSQC of
EloBC (Figure 5A) is shown here at low contrast. Most of the very
intense peaks observed were assigned to residues 101 to 118 of
EloB. The peaks assigned to residues 101 to 104 are highlighted.
(B) The structure of EloBC in complex with SOCS2 is shown
(PDB ID: 2C9W), with the a-helix formed by residues 101 to 104
of EloB highlighted. SOCS2 was omitted for clarity.
Found at: doi:10.1371/journal.ppat.1000925.s004 (0.77 MB TIF)
Figure S5 Relaxation measurements for EloB. T1 and T2
relaxation measurement spectra were recorded on
15N-labelled
free EloBC and bound to the Vif SOCS-box protein. The T1/T2
ratios were calculated for the intense peaks corresponding to
residues 101–118 of EloB.
Found at: doi:10.1371/journal.ppat.1000925.s005 (0.26 MB TIF)
Figure S6 Controls for measurements of the Vif-EloB interac-
tion. (A) ITC titration of the Vif BC-box protein against the Vif
SOCS-box DSLQ protein. No heat release is observed, confirming
that the binding recorded with the EloBC-Vif BC-box complex
(Fig. 7B) is not caused by the BC-box. (B) ITC titration of an
EloBC-Vif BC-box complex against the double mutant
(DSLQ+DPPL) Vif SOCS-box protein. No heat release is
observed, confirming that the binding recorded with the Vif
SOCS-box DSLQ mutant (Fig. 7B) is dependent on the integrity of
the PPLP motif. (C) Approximately 10 mg of purified EloBC and
EloBCD were run on a 16% polyacrylamide SDS-PAGE gel and
stained with Coomassie blue. (D) ITC titration of an EloBCD-Vif
BC-box complex against the Vif SOCS-box DSLQ mutant. No
heat release is observed, and the endothermic reaction observed
with the EloBCD-Vif BC-box complex (Fig. 7C) is not present
either.
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Figure S7 The LPLP motif of SOCS2. The crystal structure of
EloBC bound to SOCS2 (PDB ID: 2C9W) is shown, with EloBC
in surface representation; hydrophobic areas are shown in red.
The side chains of the LPLP motif of SOCS2 are highlighted. It
appears that the side chains of this motif are buried in a
hydrophobic pocket formed by EloC and the C-terminal helix of
EloB, suggesting a binding mode similar to what is proposed for
HIV-1 Vif.
Found at: doi:10.1371/journal.ppat.1000925.s007 (5.38 MB TIF)
Table S1 Chemical shift mapping for the Vif SOCS-box protein
upon binding to EloBC. Residues 3 to 58 correspond to the SET
tag, and the appended Vif residues, 139 to 171, are numbered
according to their position in the full-length Vif sequence and are
indicated in bold font. The chemical shifts were measured using
Sparky, and the combined chemical shift difference was calculated
with the equation combined shift difference=[(proton
shifts)
2+(nitrogen shifts/6.51)
2]
0.5. Non-assigned residues,
as well as residues for which peaks are not observed in the
spectrum of the bound protein, are indicated.
Found at: doi:10.1371/journal.ppat.1000925.s008 (0.11 MB
DOC)
Table S2 Relaxation measurements for the C-terminal tail of
EloB. The measurement of
15N relaxation parameters T1 and T2,
and the T1/T2 ratio displayed on Figure S5, are given for residues
101–118 of EloB, in the context of free EloBC and EloBC bound
to the Vif SOCS-box protein. The fitting of peak intensities was
obtained using NMRView.
Found at: doi:10.1371/journal.ppat.1000925.s009 (0.07 MB
DOC)
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